

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.

Learn more: [PMC Disclaimer](#) | [PMC Copyright Notice](#)

Author Manuscript

Peer reviewed and accepted for publication by a journal



J Endocrinol. Author manuscript; available in PMC: 2015 Jul 1.

Published in final edited form as: *J Endocrinol*. 2014 Jul 2;223(1):M1–M15. doi: [10.1530/JOE-14-0224](https://doi.org/10.1530/JOE-14-0224)

Morbid Obesity Attenuates the Skeletal Abnormalities Associated with Leptin Deficiency in Mice

[Russell T Turner](#)^{1,2}, [Kenneth A Philbrick](#)¹, [Carmen P Wong](#)¹, [Dawn A Olson](#)¹, [Adam J Branscum](#)³, [Urszula T Iwaniec](#)^{1,2}

[Author information](#) [Article notes](#) [Copyright and License information](#)

PMCID: PMC4161659 NIHMSID: NIHMS611414 PMID: [24990938](#)

The publisher's version of this article is available at [J Endocrinol](#)

Abstract

Leptin-deficient *ob/ob* mice are morbidly obese and exhibit low total bone mass and mild osteopetrosis. In order to disassociate the skeletal effects of leptin deficiency from those associated with morbid obesity, we evaluated bone mass, architecture, gene expression, and indices of bone turnover in wild type (WT) mice, *ob/ob* mice fed *ad libitum* (*ob/ob*), and *ob/ob* mice pair fed to WT mice (pair-fed *ob/ob*). Mice were maintained at 32°C (thermoneutral) from 6 to 18 weeks of age to minimize differences in resting energy expenditure. *ob/ob* mice were heavier, had more abdominal white adipose tissue (WAT), and were hyperglycemic compared to WT mice. Femur length, bone mineral content (BMC) and bone mineral density, and midshaft femur cortical thickness were lower in *ob/ob* mice than in WT mice. Cancellous bone volume fraction was higher but indices of bone formation and resorption were lower in *ob/ob* compared to WT mice; reduced bone resorption in *ob/ob* mice resulted in pathological retention of calcified cartilage.

Pair-fed *ob/ob* mice were lighter, had lower WAT, uterine weight, and serum glucose than *ob/ob* mice. Similarly, femoral length, BMC, and cortical thickness were lower in pair-fed *ob/ob* mice compared to *ob/ob* mice, as were indices of cancellous bone formation and resorption. In contrast, bone marrow adiposity, calcified cartilage and cancellous bone volume fraction were higher at one or more cancellous sites in pair-fed *ob/ob* mice compared to *ob/ob* mice. These findings demonstrate that the skeletal abnormalities caused by leptin deficiency are markedly attenuated in morbidly obese *ob/ob* mice.

Keywords: obesity, histomorphometry, microcomputed tomography, dual energy absorptiometry

Introduction

Leptin, a polypeptide hormone secreted by adipocytes, is best known for its role in the regulation of appetite and energy metabolism ([Mistry, et al. 1997](#); [Myers 2004](#)). Rodents deficient in leptin signaling, due to either an inability to generate leptin (*ob/ob* mice) or the signaling form of the leptin receptor (*db/db* mice and *fa/fa* rats), become morbidly obese ([Clement 2000](#)). Their excess weight is the result of a combination of hyperphagia and reduced thermogenesis ([Hwa, et al. 1996](#)). In addition to morbid obesity, leptin deficiency is associated with hypogonadism ([Barkan, et al. 2005](#)), elevated corticosteroid levels ([Saito and Bray 1983](#)), and impaired thermoregulation ([Trayhurn and James 1978](#)).

Leptin-deficient mice and leptin receptor-deficient mice and rats have reduced overall bone mass, reduced longitudinal bone growth ([Kishida, et al. 2005](#); [Steppan, et al. 2000](#)), and decreased bone formation ([Gat-Yablonski and Phillip 2008](#)). In addition, impaired bone resorption in *ob/ob* and *db/db* mice results in mild osteopetrosis ([Turner, et al. 2013](#)), a condition which may contribute to the reported reductions in bone quality observed in these animals ([Ealey, et al. 2006](#); [Kimura, et al. 2012](#)). Impaired bone resorption may also account for the age- and bone-dependent variation in cancellous bone volume observed in leptin signaling-deficient mice; the mutant mice are reported to have normal to increased cancellous bone volume fraction in lumbar vertebra and decreased to increased cancellous bone volume fraction in long bones ([Hamrick, et al. 2004](#); [Iwaniec, et al. 2007](#); [Williams, et al. 2011](#)). The skeletal abnormalities observed in mice and rats with defective leptin signaling suggest that leptin plays a role in normal skeletal growth, maturation, and turnover ([Bartell, et al. 2011](#); [Iwaniec et al. 2007](#); [Kishida et al. 2005](#); [Steppan et al. 2000](#); [Turner et al. 2013](#)). However, it is not clear to what extent the skeletal phenotype of *ob/ob* mice is impacted by additional factors associated with morbid obesity.

Although rare in humans, leptin signaling deficiency occurs as a result of loss of function mutations in the genes for leptin and the leptin receptor ([Friedman and Halaas 1998](#)). More common causes for low leptin signaling in humans include anorexia and starvation ([Dardeno, et al. 2010](#); [Muller, et al. 2009](#)). At the other end of the spectrum, diet-induced leptin resistance, associated with chronically elevated leptin levels, mimics many of the metabolic consequences of leptin deficiency on energy metabolism and is thought to contribute to development of morbid obesity ([Jung and Kim 2013](#)). Thus, changes in leptin levels and/or leptin sensitivity could have physiological effects on bone

metabolism.

In order to better understand the specific actions of leptin in regulating bone mass, density and architecture, we performed a study in which differences in body weight gain between rapidly growing wild type (WT) and *ob/ob* mice were prevented by housing all mice at thermoneutral temperature (32°C) to minimize differences in resting energy expenditure ([Trayhurn 1979](#)) and pair-feeding the mutant mice to WT mice to equalize food intake.

Materials and Methods

Experimental Design

The experimental protocols were approved by the Institutional Animal Care and Use Committee in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Four-week-old female *ob/ob* (n=20) and homozygous WT (+/+) littermate (n=11) mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). At 6 weeks of age, all animals were transferred from normal room temperature (22°C) to thermoneutral temperature (32°C) and maintained at thermoneutrality on a 12-h light, 12-h dark cycle for the duration of study (12 weeks). Food (Teklad 8604, Harlen Laboratories, Indianapolis, IN) and water were provided *ad libitum* to WT mice (n=11) and a group of *ob/ob* mice (n=10). A second group of *ob/ob* mice (n=10) was pair-fed to the WT mice; the *ob/ob* mice were fed an amount of food equivalent to the group mean for WT mice.

Food consumption was measured daily in WT mice and weekly in the *ad libitum*-fed *ob/ob* mice. Body weight was recorded weekly in all mice. The fluorochrome declomycin (20 mg/kg, Sigma, St Louis, MO) was administered at study initiation and the fluorochrome calcein (20 mg/kg, Sigma, St Louis, MO) was administered 4 days and 1 day prior to sacrifice to label mineralizing bone. All mice were fasted overnight. The mice were then anesthetized with 2–3% isoflurane delivered in oxygen, bled by cardiac puncture, and glucose measured using a glucometer (Life Scan Inc, Milpitas, CA). Serum was collected and stored at –80°C for measurement of global markers of bone turnover. Uteri and abdominal white adipose tissue (WAT) were excised and weighed. Femora and lumbar vertebrae were removed and stored in 70% ethanol for analysis using dual energy absorptiometry (DXA), microcomputed tomography (μCT), and histomorphometry. Tibiae were removed, cleaned of soft tissue, frozen in liquid nitrogen, and stored at –80°C for mRNA isolation and gene expression analysis.

Serum Chemistry

Serum osteocalcin was measured using mouse Gla-osteocalcin High Sensitive EIA kit from Clontech (Mountain View, CA). Serum CTx was measured using mouse CTx ELISA kit from Life Sciences Advanced Technologies (Saint Petersburg, FL).

Dual Energy X-ray Absorptiometry

Femoral bone mineral content (BMC, mg), area (cm²), and bone mineral density (BMD, g/cm²) were determined *ex vivo* using DXA (Piximus, Lunar Corp., Madison, WI, USA).

Microcomputed Tomography

μCT was used for nondestructive three-dimensional evaluation of bone microarchitecture ([Bouxsein, et al. 2010](#)). Femora and lumbar vertebrae were scanned in 70% ethanol using a Scanco μCT40 scanner (Scanco Medical AG, Basserdorf, Switzerland) at a voxel size of 12 × 12 × 12 μm (55 kV_p x-ray voltage, 145 μA intensity, and 200 ms integration time). Evaluations were conducted with filtering parameters sigma and support set to 0.8 and 1, respectively. Bone segmentation was performed at a threshold of 245 (scale, 0–1000) determined empirically. Total femur was evaluated followed by evaluation of cortical bone in the midshaft femur and cancellous bone in the distal femur metaphysis and epiphysis. Automated contouring was used to delineate cortical bone from non-bone. Following, all cortical slices were examined visually for potential inclusion of cancellous struts originating from the endocortex (extremely rare at this site) and manually removed when present. For cortical bone, 20 slices (0.24 mm) of bone were evaluated, and cross-sectional tissue volume (cortical and marrow volume, mm³), cortical volume (mm³), marrow volume (mm³), and cortical thickness (μm) measured. Polar moment of inertia was determined as a surrogate measure of bone strength in torsion. Architectural parameters are expressed using standard 3-dimensional nomenclature. For the femoral metaphysis, 40 slices (480 μm) of cancellous bone were evaluated. The entire cancellous compartment was assessed in the femoral epiphysis. Analysis of lumbar vertebra included the entire region of cancellous bone between the cranial and caudal growth plates. Manual contouring was used to delineate cancellous from cortical bone in the femur metaphysis, femur epiphysis, and vertebral body. Cancellous bone measurements in femur and lumbar vertebra included bone volume fraction (bone volume/tissue volume, BV/TV, %), connectivity density (mm⁻³), trabecular number (mm⁻¹), trabecular thickness (mm) and trabecular separation (mm) ([Thomsen, et al. 2005](#)).

Histomorphometry

The histological methods used here have been described in detail ([Iwaniec, et al. 2008](#)). In brief, the distal femur was dehydrated in graded series of ethanol and xylene and embedded undecalcified in modified methyl methacrylate. Sections (4 μm thick) were cut with a vertical bed microtome (Leica/Jung 2165) and affixed to slides precoated with a 1% gelatin solution. Sections were mounted unstained for measurement of fluorochrome labels. For cell-based measurements, sections were stained for tartrate resistant acid phosphatase and counterstained with toluidine blue (Sigma, St Louis). All data were collected using the OsteoMeasure System (OsteoMetrics, Inc., Atlanta, GA). The sampling site for the distal femoral metaphysis was located 0.25–1.25 mm proximal to the growth plate. The entire cancellous compartment was evaluated in the distal femoral epiphysis and body of lumbar vertebra.

Fluorochrome-based measurements of bone formation included: (1) mineralizing perimeter (mineralizing perimeter/bone perimeter: cancellous bone perimeter covered with double plus half single label normalized to bone perimeter, %), (2) mineral apposition rate (the distance between two fluorochrome markers that comprise a double label divided by the 3 day interlabel interval, $\mu\text{m}/\text{day}$), and (3) bone formation rate (bone formation rate/bone perimeter: calculated by multiplying mineralizing perimeter by mineral apposition rate normalized to bone perimeter, $\mu\text{m}^2/\mu\text{m}/\text{y}$).

Declomycin label retained in the regions of interest (mm label/ mm^2 tissue area) in the distal femur epiphysis and lumbar vertebra was measured as a dynamic index of bone resorption in *ob/ob* and pair-fed *ob/ob* mice. This method is based on the principle that declomycin label was incorporated into bone at equivalent rates in both groups of *ob/ob* mice when the fluorochrome was administered prior to treatment initiation and differences measured at study termination reflect the effect of treatment on resorption of the fluorochrome-labeled bone. This method has been described ([Westerlind, et al. 1997](#)). We did not measure declomycin label in WT mice because almost no label was retained in this group at termination of study.

Cell-based measurements included osteoblast perimeter, osteoclast perimeter, adipocyte number, and adipocyte area. Osteoblast perimeter was determined as a percentage of total bone perimeter lined by a palisade of plump cuboidal cells located immediately adjacent to the thin layer of osteoid in direct physical contact with the bone perimeter (osteoblast perimeter/bone perimeter, %). Osteoclast perimeter was determined as the percentage of cancellous bone perimeter covered by multinucleated (two or more nuclei) cells with acid phosphatase positive (red-stained) cytoplasm (osteoclast perimeter/bone perimeter, %). Cartilage area in the distal femur metaphysis and epiphysis was measured and expressed as % cancellous bone area. The intense metachromatic (purple) staining of proteoglycans and glycosaminoglycans with toluidine blue was used to identify cartilage within trabeculae. Adipocyte number and area were also measured and expressed as bone marrow adiposity (tissue area occupied by adipocytes: adipocyte area/tissue area, %), and adipocyte density (number of adipocytes/ mm^2). Adipocytes were identified morphologically as large ($> 75 \mu\text{m}^2$) circular or oval-shaped cells bordered by a prominent cell membrane and lacking cytoplasmic staining due to alcohol extraction of intracellular lipids during processing. This method was previously validated by fat extraction and analysis ([Menagh, et al. 2010](#)). All histomorphometric data are expressed using standard 2-dimensional nomenclature ([Dempster, et al. 2013](#)) to distinguish 2-dimensional histomorphometric measurements from 3-dimensional μCT measurements.

Gene Expression

Tibiae were pulverized with a mortar and pestle in liquid nitrogen and then further homogenized in Trizol (Invitrogen; Valencia, CA). Total RNA was isolated according to the manufacturer's protocol, and mRNA was reverse transcribed into cDNA using SuperScript III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen). The expression of 84 genes related to osteogenic differentiation was determined using the Mouse Osteogenesis RT² Profiler™ PCR Array (Qiagen; Carlsbad, CA) according to the manufacturer's protocol. Gene expression was normalized to GAPDH and relative quantification was determined using the $\Delta\Delta\text{Ct}$ method using RT² Profiler PCR Array Data Analysis software


Statistics

Mean responses of individual variables were compared between the WT, *ob/ob*, and pair-fed *ob/ob* groups using separate one-way analysis of variance (ANOVA), with Tukey's procedure for pairwise multiple comparisons. The required conditions for valid use of ANOVA models were assessed using Levene's test for homogeneity of variance, plots of residuals versus fitted values, normal quantile plots, and the Anderson-Darling test of normality. A modified F test was used when the assumption of equal variance was violated, with Welch's two-sample t-test used for pairwise comparisons ([Welch 1951](#)). The Kruskal-Wallis nonparametric test was used when only the normality assumption was violated, in which case the Wilcoxon-Mann-Whitney test was used for pairwise comparisons. Longitudinal data on body weight were analyzed using a random intercept linear mixed model that allowed distinct linear rates of change for the WT and pair-fed *ob/ob* groups and a quadratic time trend for the *ob/ob* group. The Hommel method for maintaining the family-wise error rate at 5% was used to adjust for multiple comparisons ([Hommel 1988](#)). Data analysis was performed using R version 2.12. Gene expression analysis was performed using RT² Profiler PCR Array Data Analysis version 3.5 (Qiagen). Gene expression is reported as mean fold change. All other data are reported as mean \pm SE.

Results

The effects of pair feeding (to match food intake in WT mice) on body weight and cumulative food intake, and on abdominal WAT weight, blood glucose levels, uterine weight, and serum osteocalcin and CTx levels at sacrifice in leptin-deficient *ob/ob* mice housed at thermoneutral temperature are shown in [Figure 1](#). Six-week-old *ob/ob* mice were heavier than their age-matched WT littermates at start of treatment and gained more weight than the WT mice during the 12-week study ([Figures 1A and B](#)). *ob/ob* mice were hyperphagic consuming, on average, twice as much food as WT mice ([Figure 1C](#)). At termination of study, the *ob/ob* mice had more abdominal WAT ([Figure 1D](#)), and were hyperglycemic ([Figure 1E](#)) and hypogonadal ([Figure 1F](#)) compared to WT mice.

Figure 1.



Effects of morbid obesity on body weight (A), cumulative body weight change (B), cumulative food intake (C), abdominal white adipose tissue (WAT) weight (D), blood glucose (E), uterine weight (F), and serum osteocalcin (G) and CTx levels (H) in leptin-deficient *ob/ob* mice. Values are mean \pm SE, n=10–11/group. ND, no data due to insufficient serum for measurement of CTx in pair-fed *ob/ob* mice. ^aDifferent from WT mice, $p < 0.05$. ^bDifferent from *ob/ob* mice, $p < 0.05$.

Pair-fed *ob/ob* mice had lower body weight and body weight gain, lower cumulative food intake, lower abdominal WAT weight, lower blood glucose levels, and slightly lower uterine weight than *ob/ob* mice. Pair-feeding abolished differences in weight gain and blood glucose levels between WT and *ob/ob* mice. However, the pair-fed *ob/ob* mice were still heavier, had more WAT, and were hypogonadal compared to WT mice.

Effects of pair feeding on serum markers of bone turnover in *ob/ob* mice

Serum levels of osteocalcin ([Figure 1G](#)) and CTx ([Figure 1H](#)) were lower in *ob/ob* mice than in WT mice. Also, pair-fed *ob/ob* mice had lower serum osteocalcin levels than either WT or *ob/ob* mice. Insufficient serum was available for measurement of CTx in pair-fed *ob/ob* mice.

Effects of pair feeding on bone mass and architecture in *ob/ob* mice

The effects of pair feeding on femur BMC, area and BMD, and on femur length, bone volume, and cortical and cancellous bone architecture in *ob/ob* mice are shown in [Table 1](#). *ob/ob* mice had lower femur BMC, bone area, and BMD than WT mice. Pair-fed *ob/ob* mice had lower BMC and bone area than WT or *ob/ob* mice. Significant differences in BMD were not detected between *ob/ob* and pair-fed *ob/ob* mice.

Table 1.

Effects of morbid obesity on femoral bone mineral content and density, femoral cortical and cancellous bone microarchitecture, and vertebral cancellous bone microarchitecture in leptin-deficient *ob/ob* mice.

End Point	WT	<i>ob/ob</i>	<i>ob/ob</i> (pair-fed)	ANOVA P _{__} *
Dual Energy X-ray Absorptiometry				
Total Femur				
BMC (g)	0.023 ± 0.000	0.019 ± 0.000 _a	0.017 ± 0.000 _{a, b}	0.0001
Bone area (cm ²)	0.43 ± 0.01	0.40 ± 0.00 _a	0.37 ± 0.01 _{a, b}	0.0001
BMD (g/cm ²)	0.053 ± 0.001	0.048 ± 0.000 _a	0.047 ± 0.000 _a	0.0003
Microcomputed Tomography				
Total Femur				
Length (mm)	14.9 ± 0.1	14.2 ± 0.1 _a	13.4 ± 0.1 _{a, b}	<0.0001
Bone volume (mm ³)	18.5 ± 0.3	16.8 ± 0.3 _a	15.0 ± 0.3 _{a, b}	<0.0001
Midshaft Femur (cortical bone)				
Cross-sectional volume (mm ³)	0.41 ± 0.01	0.40 ± 0.01	0.42 ± 0.01	0.4220
Cortical volume (mm ³)	0.20 ± 0.00	0.18 ± 0.00 _a	0.17 ± 0.00 _{a, b}	0.0008
Marrow volume (mm ³)	0.22 ± 0.00	0.23 ± 0.00	0.25 ± 0.01 _{a, b}	0.0012
Cortical thickness (μm)	195 ± 3	176 ± 3 _a	159 ± 2 _{a, b}	0.0001
Polar moment of inertia (mm ⁴)	0.36 ± 0.01	0.33 ± 0.01	0.33 ± 0.01	0.4220
Distal Femur Metaphysis (cancellous bone)				
Bone volume/tissue volume (%)	11.2 ± 0.8	13.2 ± 0.5 _a	18.1 ± 0.5 _{a, b}	0.0004
Connectivity density (1/mm ³)	106 ± 9	173 ± 7 _a	190 ± 8 _a	<0.0001
Trabecular thickness (μm)	44 ± 1	41 ± 1	45 ± 0 _b	0.0365
Trabecular number (mm ⁻¹)	4.8 ± 0.1	5.2 ± 0.1 _a	5.7 ± 0.1 _{a, b}	0.0001
Trabecular separation (μm)	210 ± 4	191 ± 4 _a	173 ± 4 _{a, b}	0.0013
Distal Femur Epiphysis (cancellous bone)				
Bone volume/tissue volume (%)	31.2 ± 0.6	36.1 ± 0.6 _a	36.6 ± 0.9 _a	0.0013

End Point	WT	<i>ob/ob</i>	<i>ob/ob</i> (pair-fed)	ANOVA P _{__} *
Connectivity density (1/mm ³)	155 ± 4	254 ± 8 _a	261 ± 7 _a	<0.0001
Trabecular thickness (μm)	64 ± 1	60 ± 1 _a	58 ± 1 _a	0.0001
Trabecular number (mm ⁻¹)	5.5 ± 0.1	6.7 ± 0.1 _a	6.7 ± 0.1 _a	0.0004
Trabecular separation (μm)	179 ± 2	138 ± 3 _a	138 ± 3 _a	<0.0001
Lumbar Vertebra (cancellous bone)				
Bone volume/tissue volume (%)	21.8 ± 1.0	31.5 ± 0.8 _a	34.2 ± 0.5 _{a, b*}	<0.0001
Connectivity density (1/mm ³)	198 ± 10	364 ± 15 _a	191 ± 5 _b	<0.0001
Trabecular thickness (μm)	49 ± 1	50 ± 0.5	54 ± 0.4 _{a, b}	0.0010
Trabecular number (mm ⁻¹)	4.6 ± 0.1	6.0 ± 0.1 _a	5.8 ± 0.1 _a	0.0004
Trabecular separation (μm)	215 ± 5	160 ± 3 _a	163 ± 3 _a	0.0005

[Open in a new tab](#)

Data are mean ± SE

*The Hommel method for maintaining the family-wise error rate at 5% was used to adjust for multiple comparisons

^aDifferent from WT, $p < 0.05$

^bDifferent from *ob/ob*, $p < 0.05$

Femur length and bone volume

ob/ob mice had shorter femurs and lower femoral bone volume than WT mice. Pair-fed *ob/ob* mice had lower femur length and lower total femur bone volume than WT or *ob/ob* mice.

Cortical bone in midshaft femur

ob/ob mice had lower cortical bone volume and cortical thickness than WT mice. Pair-fed *ob/ob* mice had lower midshaft femur cortical bone volume and cortical thickness, and greater marrow volume than WT or *ob/ob* mice. Significant differences in cross-sectional volume and polar moment of inertia were not detected among groups.

Cancellous bone in distal femur metaphysis

ob/ob mice had higher cancellous bone volume fraction, connectivity density, and trabecular number, and lower trabecular separation than WT mice. Differences in trabecular thickness were not detected between the two groups. Pair-fed *ob/ob* mice had higher cancellous bone volume fraction and trabecular number, and lower trabecular separation than WT mice or *ob/ob* mice, and higher connectivity density than WT mice. Trabecular thickness in pair-fed *ob/ob* mice was higher than in *ob/ob* mice but did not differ from WT mice.

Cancellous bone in distal femur epiphysis

ob/ob mice and pair-fed *ob/ob* mice had higher bone volume fraction, connectivity density, and trabecular number, and lower trabecular thickness and separation than WT mice. Differences between *ob/ob* mice and pair-fed *ob/ob* mice were not detected for any epiphyseal endpoint measured.


The effects of pair feeding on cancellous bone mass and architecture in lumbar vertebra in *ob/ob* mice are shown in [Table 1](#). *ob/ob* mice had higher cancellous bone volume fraction, connectivity density, and trabecular number, and lower trabecular separation than WT mice. Pair-fed *ob/ob* mice had higher bone volume fraction than WT mice and a tendency ($p < 0.1$) for higher bone volume fraction than *ob/ob* mice. Also, pair-fed *ob/ob* mice had higher trabecular thickness than WT or *ob/ob* mice. Connectivity density was lower in pair-fed *ob/ob* mice than in *ob/ob* mice but did not differ from WT mice. Trabecular number was higher and trabecular separation was lower in pair-fed *ob/ob* mice than WT mice. Differences in trabecular number and separation were not detected between *ob/ob* mice and pair-fed *ob/ob* mice.

Effects of pair feeding on bone histomorphometry in *ob/ob* mice

Cancellous bone in distal femur metaphysis








The effects of pair feeding on dynamic and static cancellous bone histomorphometry and marrow adiposity in the distal femur metaphysis in *ob/ob* mice are shown in [Figure 2](#). *ob/ob* mice had lower mineralizing perimeter ([Figure 2A](#)), mineral apposition rate ([Figure 2B](#)), bone formation rate ([Figure 2C](#)), and osteoblast perimeter ([Figure 2D](#)) compared to WT mice. Pair-fed *ob/ob* mice had lower mineralizing perimeter, mineral apposition rate, bone formation rate, and osteoblast perimeter than WT or *ob/ob* mice. Differences in osteoclast perimeter ([Figure 2E](#)) were not detected with treatment. However, cartilage area ([Figure 2F](#)), an index of impaired bone resorption, was higher in both groups of *ob/ob* mice compared to WT mice. Bone marrow adiposity ([Figure 2G](#)) tended ($p < 0.1$) to be greater in *ob/ob* mice than WT mice and was greater in pair-fed *ob/ob* mice than in WT or *ob/ob* mice. Adipocyte density ([Figure 2H](#)) was higher in pair-fed *ob/ob* mice than in *ob/ob* mice. Representative photomicrographs of marrow adipocytes in the 3 groups of mice are shown in [Figure 3A–C](#).

Figure 2.



Effects of morbid obesity on cancellous bone histomorphometry and marrow adiposity in distal femur metaphysis in leptin-deficient *ob/ob* mice. Shown are mineralizing perimeter (A, mineralizing perimeter/bone perimeter, M.Pm/B.Pm), mineral apposition rate (B, MAR), bone formation rate (C, bone formation rate/bone perimeter, BFR/B.Pm), osteoblast perimeter (D, osteoblast perimeter/bone perimeter, Ob.Pm/B.Pm), osteoclast perimeter (E, osteoclast perimeter/bone perimeter, Oc.Pm/B.Pm), cartilage area (F, cartilage area/bone area, Cg.Ar/B.Ar), marrow adiposity (G, adipocyte area/tissue area, Ad.Ar/T.Ar), and adipocyte density (H, number of adipocytes/tissue area, N.Ad/T.Ar). Values are mean \pm SE, n=10–11/group. ^aDifferent from WT mice, $p < 0.05$. ^{a*}Different from WT mice, $p < 0.1$. ^bDifferent from *ob/ob* mice, $p < 0.05$.

Figure 3.




Representative photomicrographs of 1) marrow adiposity in distal femur metaphysis in WT mouse (A), *ob/ob* mouse (B), and pair-fed *ob/ob* mouse (C), 2) cartilage remnants in distal femur epiphysis in WT mouse (D), *ob/ob* mouse (E), and pair-fed *ob/ob* mouse (F), and 3) declomycin label administered at study initiation in distal femur epiphysis in WT mouse (G), *ob/ob* mouse (H), and pair-fed *ob/ob* mouse (I).

Cancellous bone in distal femur epiphysis

The effects of pair feeding on dynamic and static cancellous bone histomorphometry and marrow adiposity in the distal femur epiphysis in *ob/ob* mice are shown in [Figure 4](#). *ob/ob* mice had lower mineralizing perimeter ([Figure 4A](#)), bone formation rate ([Figure 4C](#)), and osteoblast perimeter ([Figure 4D](#)) than WT mice. Pair-fed *ob/ob* mice had lower mineralizing perimeter, bone formation rate, and osteoblast perimeter than WT or *ob/ob* mice. Osteoclast perimeter ([Figure 4E](#)) was higher in *ob/ob* mice and pair-fed *ob/ob* mice than WT mice. Retention of declomycin label ([Figure 4F](#)), an index of decreased bone resorption, was higher in pair-fed *ob/ob* mice than in *ob/ob* mice. *ob/ob* mice had greater cartilage area ([Figure 4G](#)), marrow adiposity ([Figure 4H](#)), and adipocyte density ([Figure 4I](#)) than WT mice. Pair-fed *ob/ob* mice had higher cartilage area, marrow adiposity, and adipocyte density than WT or *ob/ob* mice. Representative photomicrographs of cartilage and declomycin label in the 3 groups are shown in [Figure 3D–F and G–I](#), respectively.

Figure 4.




[Open in a new tab](#)

Effects of morbid obesity on cancellous bone histomorphometry and marrow adiposity in distal femur epiphysis in leptin-deficient *ob/ob* mice. Shown are mineralizing perimeter (A, mineralizing perimeter/bone perimeter, M.Pm/B.Pm), mineral apposition rate (B, MAR), bone formation rate (C, bone formation rate/bone perimeter, BFR/B.Pm), osteoblast perimeter (D, osteoblast perimeter/bone perimeter, Ob.Pm/B.Pm), osteoclast perimeter (E, osteoclast perimeter/bone perimeter, Oc.Pm/B.Pm), declomycin label perimeter (F, declomycin label perimeter/bone area, declomycin L.Pm/B.Ar), cartilage area (G, cartilage area/bone area, Cg.Ar/B.Ar), marrow adiposity (H, adipocyte area/tissue area, Ad.Ar/T.Ar), and adipocyte density (I, number of adipocytes/tissue area, N.Ad/T.Ar). Values are mean \pm SE, n=10–11/group. ^aDifferent from WT mice, $p < 0.05$. ^bDifferent from *ob/ob* mice, $p < 0.05$.

Cancellous bone in lumbar vertebra

The effects of pair feeding on dynamic and static cancellous bone histomorphometry and on bone marrow adiposity in lumbar vertebra are shown in [Figure 5](#). *ob/ob* mice had lower mineralizing perimeter ([Figure 5A](#)), bone formation rate ([Figure 5C](#)), and osteoblast perimeter ([Figure 5D](#)) than WT mice. Pair-fed *ob/ob* mice had lower mineralizing perimeter, mineral apposition rate ([Figure 5B](#)), bone formation rate, and osteoblast perimeter than WT or *ob/ob* mice. Significant differences in osteoclast perimeter ([Figure 5E](#)) were not detected among the 3 groups. However, retention of declomycin label ([Figure 5F](#)) was higher in pair-fed *ob/ob* mice than in *ob/ob* mice. *ob/ob* mice had greater marrow adiposity ([Figure 5G](#)) and adipocyte density ([Figure 5H](#)) than WT mice. Pair-fed *ob/ob* mice had higher marrow adiposity and adipocyte density than WT or *ob/ob* mice.

Figure 5.




Effects of morbid obesity on cancellous bone histomorphometry and marrow adiposity in lumbar vertebra in leptin-deficient *ob/ob* mice. Shown are mineralizing perimeter (A, mineralizing perimeter/bone perimeter, M.Pm/B.Pm), mineral apposition rate (B, MAR), bone formation rate (C, bone formation rate/bone perimeter, BFR/B.Pm), osteoblast perimeter (D, osteoblast perimeter/bone perimeter, Ob.Pm/B.Pm), osteoclast perimeter (E, osteoclast perimeter/bone perimeter, Oc.Pm/B.Pm), declomycin label perimeter (F, declomycin label perimeter/bone area, declomycin L.Pm/B.Ar), marrow adiposity (G, adipocyte area/tissue area, Ad.Ar/T.Ar), and adipocyte density (H, number of adipocytes/tissue area, N.Ad/T.Ar). Values are mean \pm SE, n=10–11/group. ^aDifferent from WT mice, $p < 0.05$. ^bDifferent from *ob/ob* mice, $p < 0.05$.

Effects of pair feeding on gene expression in tibia

The effects of pair feeding on expression of 84 genes related to osteogenesis in tibia are shown in [Figure 6](#). Compared to WT mice, expression levels of 24 genes were altered in *ob/ob* mice (7 higher and 17 lower) and 26 genes in pair-fed *ob/ob* mice (10 higher and 16 lower). The expression levels of 14 genes were altered in common in *ob/ob* and pair-fed *ob/ob* mice. Compared to *ob/ob* mice, expression levels of 11 genes (3 higher and 8 lower) were altered in pair-fed *ob/ob* mice. *ob/ob* mice exhibited reductions in several key genes related to osteoblast and osteoclast differentiation and function, including Sp7/osterix (−2.5 fold), NfkB1 (−1.2 fold), alkaline phosphatase (Alpl) (−1.5 fold), Itgam (CD11b) (−1.3 fold) and osteocalcin (Bglap) (−1.8 fold). *ob/ob* mice also exhibited reductions in genes related to cartilage formation and maturation, including col2a1 (−1.5 fold) and col10a1 (−1.7 fold). Genes whose expression were elevated include Bmpr1a (+1.3 fold) and Smad4 (+1.3 fold). Compared to WT mice, pair-fed *ob/ob* mice expressed even lower levels of osteocalcin (−3.8 fold) than observed in *ob/ob* mice and, in addition, had lower mRNA levels for the osteoclast differentiation factor Csf1 (−1.5 fold) and osteoblast differentiation factor Runx2 (−1.4 fold). Furthermore, compared to WT mice, pair-fed *ob/ob* mice had higher gene expression levels for the cytokines/growth factors TNFa (+1.6 fold) and TGFB2 (+1.3 fold).

Figure 6.



Effects of morbid obesity on expression of osteogenesis-related genes in tibia. The expression of a panel of 84 osteogenesis-related genes in the tibia of WT mice (n=6), *ob/ob* mice (n=5), and *ob/ob* mice pair-fed to the WT mice (n=5) were determined using a mouse osteogenesis gene expression array. Left panel shows hierarchical clustering analysis of genes with significantly different gene expression. Magnitude of gene expression was represented by green and red bars, indicating decreased and increased expression, respectively. The normalized mean fold-change of *ob/ob* mice and pair-fed *ob/ob* mice relative to the WT mice were shown in the right panel. ^aDifferent from WT mice, $p < 0.05$. ^bDifferent from *ob/ob* mice, $p < 0.05$.

Discussion

We investigated the contribution of excessive weight gain to the skeletal phenotype of leptin-deficient *ob/ob* mice. Mice were housed at 32°C and a group of *ob/ob* mice was pair-fed to WT mice. Housing mice at 32°C, which is within the thermoneutral range for WT and *ob/ob* mice, was expected to minimize differences in resting energy expenditure and pair feeding *ob/ob* mice to WT mice was expected to equalize energy intake ([Knehans and Romsos 1982](#); [Rafael and Herling 2000](#)). The parallel increase in body weight gain in WT mice and *ob/ob* mice pair-fed to WT mice over the 12-week duration of study demonstrates the efficacy of this approach for preventing development of morbid obesity in leptin-deficient mice.

Consistent with earlier studies ([Ealey et al. 2006](#); [Hamrick et al. 2004](#); [Iwaniec et al. 2007](#); [Williams et al. 2011](#)), *ob/ob* mice exhibited a mosaic skeletal phenotype associated with decreased bone formation due to reduced osteoblast number and activity, and defective osteoclast function. Femurs from *ob/ob* mice were smaller and had thinner cortices than those from WT mice. Furthermore, serum osteocalcin levels, mRNA levels for osteocalcin and SP7 (osterix), osteoblast perimeter and dynamic indices of bone formation were lower in *ob/ob* mice than in WT mice. However, cancellous bone volume fraction in both distal femur and lumbar vertebra was higher in the *ob/ob* mice. The higher cancellous bone volume fraction was associated with (1) greatly reduced serum CTx levels, (2) reductions in mRNA levels for NFκB, Itgam and Icam1, (3) retention of calcified cartilage, and (4) retention of fluorochrome label administered at study initiation, all indicative of a defect in bone resorption. Osteoclast perimeter was either unaffected (distal femur metaphysis and lumbar vertebra) or increased (distal femur epiphysis), indicating that reduced bone resorption in *ob/ob* mice was not due to an inability to generate osteoclasts. Taken together, these findings further support our previous observation that *ob/ob* mice exhibit mild osteopetrosis. Osteopetrosis due to a defect in osteoclast function may be responsible for the poor bone quality ([Ealey et al. 2006](#)) and defective tooth eruption ([Batt 1978, 1992](#)) reported in *ob/ob* mice.

Pair-feeding accentuated many of the abnormalities in bone size, mass, microarchitecture, gene expression, and turnover typically observed in *ob/ob* mice. Thus, chronic excessive weight gain typically present in *ob/ob* mice reduces the magnitude of skeletal effects associated with leptin deficiency. We did not adjust μ CT-derived cortical bone data for body weight differences because the association between body weight and bone size and density in growing mice varies with bone and bone compartment and this association is altered by leptin ([Iwaniec, et al. 2009](#)). However, it is clear that the weight gain due to hyperphagia in *ob/ob* mice was associated with increases in cortical bone accrual but that these gains were not commensurate with the magnitude of body weight gain.

The mechanisms for the partial protective effect of morbid obesity on bone in *ob/ob* mice are likely to be multifactorial. We have previously reported a strong positive correlation between body weight and total femur bone mass in *ob/ob* mice ([Iwaniec et al. 2009](#)). This finding provides strong evidence that the higher total and cortical bone mass in *ad libitum*-fed compared to pair-fed *ob/ob* mice are, at least in part, attributable to higher body weight. Although there have been significant recent advances in our understanding of regulation of bone metabolism by mechanotransduction, the molecular mechanism for this positive effect of weight on bone mass is largely unknown. In addition to direct effects of increased mechanical loading, changes in levels of hormones and/or growth factors may mediate additional effects of increased weight on the skeleton ([Robling 2012](#)).

We did not measure levels of insulin, glucocorticoids, or norepinephrine, factors known to be dysregulated in *ob/ob* mice ([Dubuc, et al. 1985](#); [Kim and Romsos 1990](#); [Knehans and Romsos 1982](#); [Rafael and Herling 2000](#)) and known to influence bone metabolism. However, housing food-restricted *ob/ob* mice at thermoneutral temperature has been reported to reduce abnormalities in blood glucose, insulin, glucocorticoids, and norepinephrine turnover. In contrast, *ad libitum*-fed *ob/ob* mice were reported to remain hyperglycemic and hyperinsulinemic ([Lindstrom 2007](#)). We confirmed that blood glucose levels in pair-fed *ob/ob* mice did not differ from WT mice and were much lower than in *ad-libitum*-fed *ob/ob* mice. The contribution of excess insulin secretion and other factors associated with morbid obesity to the protective effects of excess body weight ([Hickman and McElduff 1990](#); [Ituarte, et al. 1988](#); [Martineau-Doize, et al. 1986](#); [Pun, et al. 1989](#); [Yaturu 2009](#)) on cortical bone microarchitecture in *ob/ob* mice requires further investigation.

Leptin is required for gonadotropin-releasing hormone secretion ([Donato, et al. 2011](#)). As a consequence, *ob/ob* mice are severely hypogonadal ([Chehab, et al. 2002](#)). The resulting deficiency in sex steroids would be expected to play a role in the pathological skeletal changes associated with leptin deficiency because sex steroids, especially estrogen, contribute to the sexual dimorphism of the female skeleton and regulate bone turnover balance in adults ([Rickard, et al. 2008](#); [Turner, et al. 1989](#); [Turner, et al. 1994](#)). Gonadal dysfunction typically results in elevated bone turnover and cancellous osteopenia. The difference between the skeletal responses to gonadal hormone insufficiency resulting from gonadectomy (high turnover) and from leptin-deficiency (low turnover) is perplexing. However, estrogen has a tonic effect on bone resorption and leptin is required for normal osteoclast function. As a consequence, high bone turnover generally associated with estrogen deficiency may be attenuated in *ob/ob* mice due to impaired osteoclast function. We speculate that the requirement for leptin in normal osteoclast function may serve as a counter regulatory mechanism to

prevent excessive bone loss during fasting.

We did not measure sex steroid levels but the higher uterine weight in *ad libitum*-fed *ob/ob* mice compared to pair-fed *ob/ob* mice implies that morbid obesity results in a small increase in circulating estrogen. Higher estrogen levels in blood or adipose tissue may contribute to the protective skeletal effects of morbid obesity ([Gennari, et al. 2011](#); [Turner 1999](#); [Turner et al. 1994](#)). Aromatase, the enzyme responsible for conversion of androgens to estrogens, is expressed by adipocytes ([Gennari et al. 2011](#)). Thus, adipose-derived estrogen is a plausible mechanism contributing to the skeletal differences between pair-fed and *ad libitum*-fed *ob/ob* mice.

Initially heavier, *ob/ob* mice pair-fed to WT mice remained heavier than WT mice for the duration of study. We chose to equalize energy availability rather than body weight in the present study because bone accrual in rapidly growing rodents is strongly associated with energy availability and bone loss accompanies weight loss in adults ([Devlin, et al. 2010](#); [Turner and Iwaniec 2011](#)). Low leptin levels induced by caloric restriction are associated with diminished bone mass accrual whereas partial leptin signaling deficiency induced in *ad lib*-fed mice by treatment with a leptin antagonist increased body weight and bone mass accrual ([Solomon, et al. 2014](#)). However, administration of leptin increases bone formation in adult *ob/ob* mice in spite of weight loss ([Bartell et al. 2011](#); [Turner et al. 2013](#)). Thus, both adequate energy availability and leptin play important roles in bone accrual in growing mice.

In contrast to peripheral fat depots, which act as dynamic energy reservoirs to maintain circulating triglyceride and free fatty acid levels during feeding and fasting, marrow fat increases with severe weight loss as well as weight gain ([Bredella, et al. 2011](#); [Devlin 2011](#)). It is therefore unlikely that the bone marrow fat depot serves as an important energy reservoir for peripheral tissues. There is, however, evidence that bone marrow adipocytes function as negative regulators of hematopoietic lineage cell differentiation ([Dorshkind, et al. 2009](#); [Gimble, et al. 1996](#); [Naveiras, et al. 2009](#)). Bone marrow fat is increased in *ob/ob* mice and this increase is reversed by leptin treatment ([Bartell et al. 2011](#); [Hamrick, et al. 2005](#); [Hamrick et al. 2004](#)). Leptin stimulates hematopoiesis ([Fantuzzi and Faggioni 2000](#); [Trottier, et al. 2012](#)), an action that may be due to inhibition of bone marrow adipogenesis, increased lipolysis, and direct stimulatory actions on hematopoietic cells. Adipocytes and osteoblasts are derived from the same bone marrow mesenchymal precursor and a reciprocal association between osteoblast number and adipocyte number has often been noted, giving rise to the hypothesis that bone marrow adipocytes may either antagonize osteoblast production or, alternatively, generation of adipocytes precludes generation of osteoblasts ([Akune, et al. 2004](#)). Other studies suggest that adipocyte and osteoblast number in bone marrow can be independently regulated ([Iwaniec and Turner 2013](#); [Menagh et al. 2010](#)). [Bartell et al. \(2011\)](#) reported that intracerebroventricular administration of leptin to *ob/ob* mice increases expression of SP7, a transcription factor critical for osteoblast differentiation. Our findings of low expression of SP7 in *ob/ob* mice support the hypothesis that leptin acts to regulate bone formation by controlling mesenchymal cell decision.

In the present study, pair feeding to WT mice resulted in a further increase in bone marrow adiposity in leptin-deficient *ob/ob* mice. Of interest is our finding that pair-fed *ob/ob* mice had elevated mRNA levels for CD36; CD36 (fatty acid

translocase) promotes adipocyte differentiation and adipogenesis ([Christiaens, et al. 2012](#)). The observed increase in CD36 may play a role in the increased bone marrow adiposity observed in the pair-fed *ob/ob* mice. Additional factors regulating bone marrow adiposity that may be influenced by leptin levels and obesity include growth hormone and IGF1. In rats, treatment with parathyroid hormone (whose actions on bone are largely mediated through IGF1) prevented the increase in bone marrow adiposity associated with severe energy restriction ([Turner and Iwaniec 2011](#)), whereas growth hormone treatment dramatically reduced excessive bone marrow adiposity in severely hypoleptinemic hypophysectomized rats ([Menagh et al. 2010](#)). In both of these studies, treatment had no effect on serum leptin levels. *ob/ob* mice, however, have decreased circulating growth hormone and impaired growth hormone signaling ([Luque, et al. 2007](#)), likely contributing to retention of fat within the bone marrow. High circulating insulin levels in morbidly obese *ob/ob* mice may further contribute to the suppression of growth hormone synthesis and release ([Luque and Kineman 2006](#)). However, IGF1 is produced and secreted by adipocytes ([Kloting, et al. 2008](#)) and higher levels of IGF1 are detected in obese subjects ([Frystyk, et al. 1999](#)). Low leptin levels resulting from severe energy restriction are associated with increased growth hormone secretion, decreased circulating levels of IGF1, and end-organ resistance to growth hormone ([Douyon and Schteingart 2002](#); [Grinspoon, et al. 1995](#); [Inagaki, et al. 2008](#); [Munoz and Argente 2002](#); [Thissen, et al. 1999](#)). Thus, disturbances in growth hormone, IGF1 and insulin signaling as well as leptin deficiency may contribute to the increase in bone marrow adiposity in *ob/ob* mice. Chronic hyperphagia and excessive weight gain typically observed in *ob/ob* mice may partially compensate for leptin deficiency and reduced bone marrow adiposity by altering growth hormone and insulin levels and sensitivity.

In summary, leptin deficiency resulted in decreased femur length, BMC, BMD, and cortical bone volume and thickness. In contrast, cancellous bone volume fraction was increased in distal femur and lumbar vertebra. The profound changes in bone mass, density, and microarchitecture were associated with reduced linear bone growth, increased bone marrow adiposity, altered expression of osteogenic genes, decreased osteoblast number, and decreased osteoclast function. Prevention of morbid obesity in *ob/ob* mice further exacerbated many of the abnormalities associated with leptin deficiency. Because morbid obesity normally present in *ob/ob* mice attenuates the abnormal skeletal phenotype associated with leptin deficiency, the role of leptin in regulating postnatal bone growth, maturation, and turnover may have been underestimated.

Acknowledgments

Funding: This work was supported by NIH (AR 060913), NASA (NNX12AL24), and USDA (38420-17804).

Footnotes

Declaration of Interest: The authors have nothing to disclose.

References Cited

1. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. *J Clin Invest*. 2004;113:846–855. doi: 10.1172/JCI19900. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
2. Barkan D, Hurgin V, Dekel N, Amsterdam A, Rubinstein M. Leptin induces ovulation in GnRH-deficient mice. *FASEB J*. 2005;19:133–135. doi: 10.1096/fj.04-2271fje. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
3. Bartell SM, Rayalam S, Ambati S, Gaddam DR, Hartzell DL, Hamrick M, She JX, Della-Fera MA, Baile CA. Central (ICV) leptin injection increases bone formation, bone mineral density, muscle mass, serum IGF-1, and the expression of osteogenic genes in leptin-deficient ob/ob mice. *J Bone Miner Res*. 2011;26:1710–1720. doi: 10.1002/jbmr.406. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
4. Batt RA. Abnormal dentition and decrease in body weight in the genetically obese mouse (genotype, ob/ob) *Int J Obes*. 1978;2:457–462. [[PubMed](#)] [[Google Scholar](#)]
5. Batt RA. Abnormal incisor teeth and body weight in the obese mouse (genotype ob/ob) *Int J Obes Relat Metab Disord*. 1992;16:29–34. [[PubMed](#)] [[Google Scholar](#)]
6. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. *J Bone Miner Res*. 2010;25:1468–1486. doi: 10.1002/jbmr.141. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
7. Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, Rosen CJ, Klibanski A, Miller KK. Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. *Obesity (Silver Spring)* 2011;19:49–53. doi: 10.1038/oby.2010.106. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
8. Chehab FF, Qiu J, Mounzih K, Ewart-Toland A, Ogus S. Leptin and reproduction. *Nutr Rev*. 2002;60:S39–46. doi: 10.1301/002966402320634823. discussion S68–84, 85–37. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
9. Christiaens V, Van Hul M, Lijnen HR, Scroyen I. CD36 promotes adipocyte differentiation and adipogenesis. *Biochim Biophys Acta*. 2012;1820:949–956. doi: 10.1016/j.bbagen.2012.04.001. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
10. Clement K. Monogenic forms of obesity: from mice to human. *Ann Endocrinol (Paris)* 2000;61(Suppl 6):39–49. [[PubMed](#)] [[Google Scholar](#)]
11. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Mantzoros CS. Leptin in human

physiology and therapeutics. *Front Neuroendocrinol.* 2010;31:377–393. doi: 10.1016/j.yfrne.2010.06.002. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

12. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res.* 2013;28:2–17. doi: 10.1002/jbmr.1805. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

13. Devlin MJ. Why does starvation make bones fat? *Am J Hum Biol.* 2011;23:577–585. doi: 10.1002/ajhb.21202. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

14. Devlin MJ, Cloutier AM, Thomas NA, Panus DA, Lotinun S, Pinz I, Baron R, Rosen CJ, Bouxsein ML. Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. *J Bone Miner Res.* 2010;25:2078–2088. doi: 10.1002/jbmr.82. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

15. Donato J, Jr, Cravo RM, Frazao R, Elias CF. Hypothalamic sites of leptin action linking metabolism and reproduction. *Neuroendocrinology.* 2011;93:9–18. doi: 10.1159/000322472. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

16. Dorshkind K, Montecino-Rodriguez E, Signer RA. The ageing immune system: is it ever too old to become young again? *Nat Rev Immunol.* 2009;9:57–62. doi: 10.1038/nri2471. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

17. Douyon L, Schteingart DE. Effect of obesity and starvation on thyroid hormone, growth hormone, and cortisol secretion. *Endocrinol Metab Clin North Am.* 2002;31:173–189. doi: 10.1016/s0889-8529(01)00023-8. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

18. Dubuc PU, Wilden NJ, Carlisle HJ. Fed and fasting thermoregulation in ob/ob mice. *Ann Nutr Metab.* 1985;29:358–365. doi: 10.1159/000176992. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

19. Ealey KN, Fonseca D, Archer MC, Ward WE. Bone abnormalities in adolescent leptin-deficient mice. *Regul Pept.* 2006;136:9–13. doi: 10.1016/j.regpep.2006.04.013. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

20. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. *J Leukoc Biol.* 2000;68:437–446. [[PubMed](#)] [[Google Scholar](#)]

21. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. *Nature.* 1998;395:763–770. doi: 10.1038/27376. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

22. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. *Diabetes Metab Res Rev.* 1999;15:314–322. doi:

10.1002/(sici)1520-7560(199909/10)15:5<314::aid-dmrr56>3.0.co;2-e. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

23. Gat-Yablonski G, Phillip M. Leptin and regulation of linear growth. *Curr Opin Clin Nutr Metab Care*. 2008;11:303–308. doi: 10.1097/MCO.0b013e3282f795cf. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

24. Gennari L, Merlotti D, Nuti R. Aromatase activity and bone loss. *Adv Clin Chem*. 2011;54:129–164. doi: 10.1016/b978-0-12-387025-4.00006-6. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

25. Gimble JM, Robinson CE, Wu X, Kelly KA. The function of adipocytes in the bone marrow stroma: an update. *Bone*. 1996;19:421–428. doi: 10.1016/s8756-3282(96)00258-x. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

26. Grinspoon SK, Baum HB, Kim V, Coggins C, Klibanski A. Decreased bone formation and increased mineral dissolution during acute fasting in young women. *J Clin Endocrinol Metab*. 1995;80:3628–3633. doi: 10.1210/jcem.80.12.8530611. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

27. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. *J Bone Miner Res*. 2005;20:994–1001. doi: 10.1359/JBMR.050103. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

28. Hamrick MW, Pennington C, Newton D, Xie D, Isales C. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. *Bone*. 2004;34:376–383. doi: 10.1016/j.bone.2003.11.020. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

29. Hickman J, McElduff A. Insulin sensitizes a cultured rat osteogenic sarcoma cell line to hormones which activate adenylate cyclase. *Calcif Tissue Int*. 1990;46:401–405. doi: 10.1007/BF02554971. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

30. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. *Biometrika*. 1988;75:383–386. [[Google Scholar](#)]

31. Hwa JJ, Ghibaudi L, Compton D, Fawzi AB, Strader CD. Intracerebroventricular injection of leptin increases thermogenesis and mobilizes fat metabolism in ob/ob mice. *Horm Metab Res*. 1996;28:659–663. doi: 10.1055/s-2007-979873. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

32. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. *Cell Metab*. 2008;8:77–83. doi: 10.1016/j.cmet.2008.05.006. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

33. Ituarte EA, Ituarte HG, Hahn TJ. Insulin and glucose regulation of glycogen synthase in rat calvarial

osteoblastlike cells. *Calcif Tissue Int.* 1988;42:351–357. doi: 10.1007/BF02556352. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

34. Iwaniec UT, Boghossian S, Lapke PD, Turner RT, Kalra SP. Central leptin gene therapy corrects skeletal abnormalities in leptin-deficient ob/ob mice. *Peptides*. 2007;28:1012–1019. doi: 10.1016/j.peptides.2007.02.001. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

35. Iwaniec UT, Dube MG, Boghossian S, Song H, Helferich WG, Turner RT, Kalra SP. Body mass influences cortical bone mass independent of leptin signaling. *Bone*. 2009;44:404–412. doi: 10.1016/j.bone.2008.10.058. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

36. Iwaniec UT, Turner RT. Failure to generate bone marrow adipocytes does not protect mice from ovariectomy-induced osteopenia. *Bone*. 2013;53:145–153. doi: 10.1016/j.bone.2012.11.034. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

37. Iwaniec UT, Wronski TJ, Turner RT. Histological analysis of bone. *Methods Mol Biol.* 2008;447:325–341. doi: 10.1007/978-1-59745-242-7_21. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

38. Jung CH, Kim MS. Molecular mechanisms of central leptin resistance in obesity. *Arch Pharm Res.* 2013;36:201–207. doi: 10.1007/s12272-013-0020-y. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

39. Kim HK, Romsos DR. Adrenalectomy increases brown adipose tissue metabolism in ob/ob mice housed at 35 degrees C. *Am J Physiol.* 1990;259:E362–369. doi: 10.1152/ajpendo.1990.259.3.E362. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

40. Kimura S, Sasase T, Ohta T, Sato E, Matsushita M. Characteristics of bone turnover, bone mass and bone strength in Spontaneously Diabetic Torii-Lepr fa rats. *J Bone Miner Metab.* 2012;30:312–320. doi: 10.1007/s00774-011-0324-2. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

41. Kishida Y, Hirao M, Tamai N, Nampei A, Fujimoto T, Nakase T, Shimizu N, Yoshikawa H, Myoui A. Leptin regulates chondrocyte differentiation and matrix maturation during endochondral ossification. *Bone*. 2005;37:607–621. doi: 10.1016/j.bone.2005.05.009. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

42. Kloting N, Koch L, Wunderlich T, Kern M, Ruschke K, Krone W, Bruning JC, Bluher M. Autocrine IGF-1 action in adipocytes controls systemic IGF-1 concentrations and growth. *Diabetes*. 2008;57:2074–2082. doi: 10.2337/db07-1538. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

43. Knehans AW, Romsos DR. Reduced norepinephrine turnover in brown adipose tissue of ob/ob mice. *Am J Physiol.* 1982;242:E253–261. doi: 10.1152/ajpendo.1982.242.4.E253. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

44. Lindstrom P. The physiology of obese-hyperglycemic mice [ob/ob mice] *ScientificWorldJournal*. 2007;7:666–685. doi: 10.1100/tsw.2007.117. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
45. Luque RM, Huang ZH, Shah B, Mazzone T, Kineman RD. Effects of leptin replacement on hypothalamic-pituitary growth hormone axis function and circulating ghrelin levels in ob/ob mice. *Am J Physiol Endocrinol Metab*. 2007;292:E891–899. doi: 10.1152/ajpendo.00258.2006. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
46. Luque RM, Kineman RD. Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. *Endocrinology*. 2006;147:2754–2763. doi: 10.1210/en.2005-1549. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
47. Martineau-Doize B, McKee MD, Warshawsky H, Bergeron JJ. In vivo demonstration by radioautography of binding sites for insulin in liver, kidney, and calcified tissues of the rat. *Anat Rec*. 1986;214:130–140. doi: 10.1002/ar.1092140205. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
48. Menagh PJ, Turner RT, Jump DB, Wong CP, Lowry MB, Yakar S, Rosen CJ, Iwaniec UT. Growth hormone regulates the balance between bone formation and bone marrow adiposity. *J Bone Miner Res*. 2010;25:757–768. doi: 10.1359/jbmr.091015. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
49. Mistry AM, Swick AG, Romsos DR. Leptin rapidly lowers food intake and elevates metabolic rates in lean and ob/ob mice. *J Nutr*. 1997;127:2065–2072. doi: 10.1093/jn/127.10.2065. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
50. Muller TD, Focker M, Holtkamp K, Herpertz-Dahlmann B, Hebebrand J. Leptin-mediated neuroendocrine alterations in anorexia nervosa: somatic and behavioral implications. *Child Adolesc Psychiatr Clin N Am*. 2009;18:117–129. doi: 10.1016/j.chc.2008.07.002. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
51. Munoz MT, Argente J. Anorexia nervosa in female adolescents: endocrine and bone mineral density disturbances. *Eur J Endocrinol*. 2002;147:275–286. doi: 10.1530/eje.0.1470275. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
52. Myers MG., Jr Leptin receptor signaling and the regulation of mammalian physiology. *Recent Prog Horm Res*. 2004;59:287–304. doi: 10.1210/rp.59.1.287. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
53. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. *Nature*. 2009;460:259–263. doi: 10.1038/nature08099. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
54. Pun KK, Lau P, Ho PW. The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. *J Bone Miner Res*. 1989;4:853–862. doi: 10.1002/jbmr.5650040610.

[\[DOI\]](#)] [\[PubMed\]](#) [\[Google Scholar\]](#)]

55. Rafael J, Herling AW. Leptin effect in ob/ob mice under thermoneutral conditions depends not necessarily on central satiation. *Am J Physiol Regul Integr Comp Physiol*. 2000;278:R790–795. doi: 10.1152/ajpregu.2000.278.3.R790. [\[DOI\]](#)] [\[PubMed\]](#) [\[Google Scholar\]](#)]

56. Rickard DJ, Iwaniec UT, Evans G, Hefferan TE, Hunter JC, Waters KM, Lydon JP, O'Malley BW, Khosla S, Spelsberg TC, et al. Bone growth and turnover in progesterone receptor knockout mice. *Endocrinology*. 2008;149:2383–2390. doi: 10.1210/en.2007-1247. [\[DOI\]](#)] [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)]

57. Robling AG. The interaction of biological factors with mechanical signals in bone adaptation: recent developments. *Curr Osteoporos Rep*. 2012;10:126–131. doi: 10.1007/s11914-012-0099-y. [\[DOI\]](#)] [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)]

58. Saito M, Bray GA. Diurnal rhythm for corticosterone in obese (ob/ob) diabetes (db/db) and gold-thioglucose-induced obesity in mice. *Endocrinology*. 1983;113:2181–2185. doi: 10.1210/endo-113-6-2181. [\[DOI\]](#)] [\[PubMed\]](#) [\[Google Scholar\]](#)]

59. Solomon G, Atkins A, Shahar R, Gertler A, Monsonego-Ornan E. Effect of peripherally administered leptin antagonist on whole body metabolism and bone microarchitecture and biomechanical properties in the mouse. *Am J Physiol Endocrinol Metab*. 2014;306:E14–27. doi: 10.1152/ajpendo.00155.2013. [\[DOI\]](#)] [\[PubMed\]](#) [\[Google Scholar\]](#)]

60. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. *Regul Pept*. 2000;92:73–78. doi: 10.1016/s0167-0115(00)00152-x. [\[DOI\]](#)] [\[PubMed\]](#) [\[Google Scholar\]](#)]

61. Thissen JP, Underwood LE, Ketelslegers JM. Regulation of insulin-like growth factor-I in starvation and injury. *Nutr Rev*. 1999;57:167–176. doi: 10.1111/j.1753-4887.1999.tb06939.x. [\[DOI\]](#)] [\[PubMed\]](#) [\[Google Scholar\]](#)]

62. Thomsen JS, Laib A, Koller B, Prohaska S, Mosekilde L, Gowin W. Stereological measures of trabecular bone structure: comparison of 3D micro computed tomography with 2D histological sections in human proximal tibial bone biopsies. *J Microsc*. 2005;218:171–179. doi: 10.1111/j.1365-2818.2005.01469.x. [\[DOI\]](#)] [\[PubMed\]](#) [\[Google Scholar\]](#)]

63. Trayhurn P. Thermoregulation in the diabetic-obese (db/db) mouse. The role of non-shivering thermogenesis in energy balance. *Pflugers Arch*. 1979;380:227–232. doi: 10.1007/BF00582901. [\[DOI\]](#)] [\[PubMed\]](#) [\[Google Scholar\]](#)]

64. Trayhurn P, James WP. Thermoregulation and non-shivering thermogenesis in the genetically obese (ob/

ob) mouse. *Pflugers Arch.* 1978;373:189–193. doi: 10.1007/BF00584859. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

65. Trottier MD, Naaz A, Li Y, Fraker PJ. Enhancement of hematopoiesis and lymphopoiesis in diet-induced obese mice. *Proc Natl Acad Sci U S A.* 2012;109:7622–7629. doi: 10.1073/pnas.1205129109. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

66. Turner RT. Mice, estrogen, and postmenopausal osteoporosis. *J Bone Miner Res.* 1999;14:187–191. doi: 10.1359/jbmr.1999.14.2.187. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

67. Turner RT, Hannon KS, Demers LM, Buchanan J, Bell NH. Differential effects of gonadal function on bone histomorphometry in male and female rats. *J Bone Miner Res.* 1989;4:557–563. doi: 10.1002/jbmr.5650040415. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

68. Turner RT, Iwaniec UT. Low dose parathyroid hormone maintains normal bone formation in adult male rats during rapid weight loss. *Bone.* 2011;48:726–732. doi: 10.1016/j.bone.2010.12.034. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

69. Turner RT, Kalra SP, Wong CP, Philbrick KA, Lindenmaier LB, Boghossian S, Iwaniec UT. Peripheral leptin regulates bone formation. *J Bone Miner Res.* 2013;28:22–34. doi: 10.1002/jbmr.1734. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

70. Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. *Endocr Rev.* 1994;15:275–300. doi: 10.1210/edrv-15-3-275. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

71. Welch BL. On the comparison of several mean values: an alternative approach. *Biometrika.* 1951;38:330–336. [[Google Scholar](#)]

72. Westerlind KC, Wronski TJ, Ritman EL, Luo ZP, An KN, Bell NH, Turner RT. Estrogen regulates the rate of bone turnover but bone balance in ovariectomized rats is modulated by prevailing mechanical strain. *Proc Natl Acad Sci U S A.* 1997;94:4199–4204. doi: 10.1073/pnas.94.8.4199. [[DOI](#)] [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

73. Williams GA, Callon KE, Watson M, Costa JL, Ding Y, Dickinson M, Wang Y, Naot D, Reid IR, Cornish J. Skeletal phenotype of the leptin receptor-deficient db/db mouse. *J Bone Miner Res.* 2011;26:1698–1709. doi: 10.1002/jbmr.367. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

74. Yaturu S. Diabetes and skeletal health. *J Diabetes.* 2009;1:246–254. doi: 10.1111/j.1753-0407.2009.00049.x. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]

